ROSUVASTATIN CALCIUM

Search structure


Trade Names:	CRESTOR EZALLOR ROSUVASTATIN CALCIUM
Synonyms:	Crestor Ezallor Ezallor sprinkle Fortius NSC-747274 NSC-758930 Rostar Rosuvastatin (as calcium) Rosuvastatin calcium Rosuvastatin calcium salt Rosuvastatin hemicalcium Rozavel S-4522 Suvikan ZD-4522 ZD-4522 CALCIUM ZD4522 CALCIUM ZD-4522 (CALCIUM SALT) ZD4522 (CALCIUM SALT)
Status:	Approved (2003)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	83MVU38M7Q
Parent Compound:	ROSUVASTATIN

Structure


InChI Key	LALFOYNTGMUKGG-BGRFNVSISA-L
Smile	CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]
InChI	InChI=1S/2C22H28FN3O6S.Ca/c21-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h25-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;;+2/p-2/b210-9+;/t216-,17-;/m11./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C44H54CaF2N6O12S2
Molecular Weight	1001.15
AlogP	2.4
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	10.0
Polar Surface Area	140.92
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	33.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	HMG-CoA reductase inhibitor	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	9030	-	-	-
Transporter Primary active transporter ATP-binding cassette ABCC subfamily	-	26800	-	-	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Coronary Disease	4	D003327	ClinicalTrials
Hypertriglyceridemia	3	D015228	ClinicalTrials
Ischemic Stroke	3	D000083242	ClinicalTrials
Hyperlipidemia, Familial Combined	3	D006950	ClinicalTrials
Diabetes Mellitus, Type 1	3	D003922	ClinicalTrials
Diabetes Mellitus, Type 2	3	D003924	ClinicalTrials
Heart Failure	3	D006333	ClinicalTrials
Acute Coronary Syndrome	3	D054058	ClinicalTrials
Lipid Metabolism Disorders	3	D052439	ClinicalTrials
Hypertension	3	D006973	ClinicalTrials
Diabetes Mellitus	1	D003920	ClinicalTrials

Related Entries

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Musculoskeletal and connective tissue disorders	12.79
General disorders and administration site conditions	10.54
Nervous system disorders	9.53
Cardiac disorders	8.19
Vascular disorders	8.04
Investigations	8.03
Injury, poisoning and procedural complications	6.82
Gastrointestinal disorders	5.87
Respiratory, thoracic and mediastinal disorders	4.69
Psychiatric disorders	4.58
Metabolism and nutrition disorders	3.83
Skin and subcutaneous tissue disorders	3.47
Endocrine disorders	2.28

Cross References

Resources	Reference
ChEBI	77249
ChEMBL	CHEMBL1744447
FDA SRS	83MVU38M7Q
PubChem	5282455
SureChEMBL	SCHEMBL150740

CONTENTS